Marc N. Casper - Nov 1, 2024 Form 4 Insider Report for THERMO FISHER SCIENTIFIC INC. (TMO)

Role
Chairman & CEO, Director
Signature
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper
Stock symbol
TMO
Transactions as of
Nov 1, 2024
Transactions value $
-$2,031,190
Form type
4
Date filed
11/4/2024, 04:30 PM
Previous filing
Nov 1, 2024
Next filing
Nov 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMO Common Stock Options Exercise $1.23M +5.85K +4.83% $210.68 127K Nov 1, 2024 Direct
transaction TMO Common Stock Sale -$55.1K -100 -0.08% $550.80 127K Nov 1, 2024 Direct F1
transaction TMO Common Stock Sale -$55.2K -100 -0.08% $551.59 127K Nov 1, 2024 Direct F1
transaction TMO Common Stock Sale -$55.2K -100 -0.08% $552.14 127K Nov 1, 2024 Direct F1
transaction TMO Common Stock Sale -$167K -300 -0.24% $555.01 126K Nov 1, 2024 Direct F1, F2
transaction TMO Common Stock Sale -$831K -1.49K -1.18% $557.14 125K Nov 1, 2024 Direct F1, F3
transaction TMO Common Stock Sale -$978K -1.75K -1.4% $558.15 123K Nov 1, 2024 Direct F1, F4
transaction TMO Common Stock Sale -$731K -1.31K -1.06% $559.02 122K Nov 1, 2024 Direct F1, F5
transaction TMO Common Stock Sale -$336K -600 -0.49% $560.30 121K Nov 1, 2024 Direct F1, F6
transaction TMO Common Stock Sale -$56.3K -100 -0.08% $563.19 121K Nov 1, 2024 Direct F1
holding TMO Common Stock 11.3K Nov 1, 2024 By Alison Casper 2020 Irrevocable Trust F7
holding TMO Common Stock 43.6K Nov 1, 2024 By Floral Park Associates, Inc.
holding TMO Common Stock 5K Nov 1, 2024 By MNC 2020 Irrevocable Trust F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMO Stock Option (Right to Buy) Options Exercise $0 -5.85K -100% $0.00 0 Nov 1, 2024 Common Stock 5.85K $210.68 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.59 to $555.23, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $556.62 to $557.58 inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $557.68 to $558.48, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $558.68 to $559.46, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $560.05 to $560.64, inclusive.
F7 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F8 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F9 The option vested in four equal installments on February 27, 2019, 2020, 2021, and 2022.